Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes

  • Technology appraisal guidance
  • TA317
  • Published: 
Download guidance (PDF)

8 Sources of evidence considered by the Committee

A. The assessment report for this appraisal was prepared by Liverpool Reviews and Implementation Group:

  • Greenhalgh, J, et al. (2013) Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182).

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, assessment report and the appraisal consultation document (ACD). Organisations listed in I, II and III were also invited to make written submissions and have the opportunity to appeal against the final appraisal determination.

I. Manufacturers/sponsors:

  • Eli Lilly and Company/Daiichi-Sankyo

II. Professional/specialist and patient/carer groups:

  • Pumping Marvellous Foundation

  • South Asian Health Foundation

  • British Cardiovascular Intervention Society

  • British Heart Foundation

  • Royal College of Nursing

  • Royal College of Physicians

III. Other consultees:

  • Department of Health

  • NHS Fylde & Wyre CCG

  • Welsh Government

IV. Commentator organisations (without the right of appeal):

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety- Northern Ireland

  • Health Improvement Scotland

  • Medicines and Healthcare products Regulatory Agency

C. The following individuals were selected from clinical specialist and patient expert nominations from the consultees and commentators. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on prasugrel with percutaneous coronary intervention for treating acute coronary syndrome by attending the initial Committee discussion and/or providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Professor Nick Curzen, Professor of Interventional Cardiology, nominated by British Cardiovascular Intervention Society – clinical specialist

  • Dr Tim Kinnaird, Consultant Cardiologist, nominated by Eli Lilly and Company

  • Nick Hartshorne- Evans, CEO, nominated by the Pumping Marvellous Foundation – patient expert

D. Representatives from the following manufacturers/sponsors attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Eli Lilly and Company